pci-32765 has been researched along with Brain-Diseases* in 5 studies
5 other study(ies) available for pci-32765 and Brain-Diseases
| Article | Year |
|---|---|
Cerebral aspergillosis in a patient on ibrutinib therapy.
Topics: Adenine; Adrenal Cortex Hormones; Aged; Aspergillosis; Aspergillus fumigatus; Brain Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Tomography, X-Ray Computed | 2021 |
A Case of Bing-Neel Syndrome Treated Successfully With Ibrutinib Monotherapy Following Intensive Chemoimmunotherapy.
Topics: Adenine; Aged; Brain Diseases; Central Nervous System Neoplasms; Female; Humans; Immunotherapy; Piperidines; Syndrome | 2021 |
Ibrutinib for the treatment of Bing-Neel syndrome, a complication of Waldenström macroglobulinemia: Patient case report.
Bing-Neel syndrome is a rare complication of Waldenström macroglobulinemia, characterized by infiltration of lymphoplasmacytic cells to the central nervous system. Multiple treatment modalities exist including purine analogs, bendamustine, high-dose methotrexate, or high-dose cytarabine. Of interest, ibrutinib, a Bruton tyrosine kinase inhibitor has also displayed efficacy in Bing-Neel syndrome. Current literature is limited for the treatment of Bing-Neel syndrome considering its rarity, and while ibrutinib is indicated for the treatment of Waldenström macroglobulinemia, it is utilized off-label for treatment of Bing-Neel syndrome. Additionally, debate exists regarding the recommended dosing strategy for ibrutinib for this indication with disease remission demonstrated at 560 mg and 420 mg. We present a case report that provides additional evidence for this debate with a patient who received 560 mg of ibrutinib initially and maintained disease control despite a dose reduction to 420 mg for tolerability. Ultimately, more data are needed to develop standardized Bing-Neel syndrome treatment strategies with specific consideration to the use of ibrutinib in this condition. Topics: Adenine; Brain Diseases; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Syndrome; Treatment Outcome; Waldenstrom Macroglobulinemia | 2019 |
Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia?
Topics: Adenine; Aged; Brain Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neuroaspergillosis; Opportunistic Infections; Piperidines; Pyrazoles; Pyrimidines | 2018 |
Efficacy of ibrutinib as first-line treatment of tumoral Bing-Neel syndrome.
Topics: Adenine; Aged; Brain; Brain Diseases; Humans; Magnetic Resonance Imaging; Male; Piperidines; Pyrazoles; Pyrimidines; Syndrome; Treatment Outcome; Waldenstrom Macroglobulinemia | 2018 |